Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer
Fujinami, K.; Miura, T.; Takizawa, A.; Osada, Y.
Hinyokika Kiyo. Acta Urologica Japonica 51(1): 5-8
2005
ISSN/ISBN: 0018-1994 PMID: 15732332 Document Number: 584936
We investigated the efficacy of docetaxel and cisplatin for hormone-refractory prostate cancer (HRPC). Thirteen patients with HRPC were treated with 30 mg/m(2) docetaxel weekly for 3 weeks and 70 mg/m(2) cisplatin on day 1. Treatment was repeated every 21 days. They received 2 cycles and were evaluated for the responses to serum prostate-specific antigen (PSA) and tumor size. Ten (77%) of the 13 patients showed a 50% or greater decrease in PSA with a median time to progression of 3 months. One of the 2 patients with measurable soft tissue disease showed a reduction in disease. No severe toxicity of this regimen was observed.Combination chemotherapy with docetaxel and cisplatin in patients with HRPC was well tolerated and efficatious with a significant decrease in serum PSA and measurable disease.